Evidence map›Paper›PMID 37072018›Full record

ArticleThe Lancet. Respiratory medicine2023

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.

Callum Jackson, Iain D Stewart, Tatiana Plekhanova, Peter S Cunningham, Andrew L Hazel, Bashar Al-Sheklly, Raminder Aul, Charlotte E Bolton, Trudie Chalder, James D Chalmers and 52 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The Lancet. Respiratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Pulmonary fibrosis: from mechanisms to therapies.Journal of translational medicine · 2025
    Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study.International journal of epidemiology · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

62 authors at 20 institutions in 2 countries.

Callum JacksonDepartment of Mathematics, University of Manchester, Manchester, UK.
Iain D StewartMargaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart & Lung Institute, Imperial College London, London, UK.
Tatiana PlekhanovaDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Peter S CunninghamFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Andrew L HazelDepartment of Mathematics, University of Manchester, Manchester, UK.
Bashar Al-ShekllyManchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
Raminder AulSt Georges University Hospitals NHS Foundation Trust, London, UK.
Charlotte E BoltonNottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK; NIHR Nottingham BRC respiratory theme, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
Trudie ChalderDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; Persistent Physical Symptoms Research and Treatment Unit, South London and Maudsley NHS Trust, London, UK.
James D ChalmersUniversity of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Nazia ChaudhuriUlster University, Newtownabbey, UK.
Annemarie B DochertyCentre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
Gavin DonaldsonNational Heart & Lung Institute, Imperial College London, London, UK.
Charlotte L EdwardsonDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Omer ElneimaThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Neil J GreeningThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Neil A HanleyFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
Victoria C HarrisThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK.
Ewen M HarrisonCentre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
Ling-Pei HoMRC Human Immunology Unit, University of Oxford, Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK.
Linzy Houchen-WolloffCentre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Department of Respiratory Sciences, University of Leicester, Leicester, UK; Therapy Department, University Hospitals of Leicester, NHS Trust, Leicester, UK.
Luke S HowardImperial College Healthcare NHS Trust, London, UK; Imperial College London, London, UK.
Caroline J JolleyFaculty of Life Sciences & Medicine, King's College Hospital NHS Foundation Trust, London, UK; Kings College London, London, UK.
Mark G JonesClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospitals Southampton, Southampton, UK.
Olivia C LeavyDepartment of Population Health Sciences, University of Leicester, Leicester, UK.
Keir E LewisHywel Dda University Health Board, Wales, UK; University of Swansea, Wales, UK; Respiratory Innovation Wales, Wales, UK.
Nazir I LoneThe Usher Institute, University of Edinburgh, Edinburgh, UK; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Michael MarksDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, University College London Hospital, London, UK; Division of Infection and Immunity, University College London, London, UK.
Hamish J C McAuleyThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Melitta A McNarryDepartment of Sport and Exercise Sciences, Swansea University, Swansea, UK.
Brijesh V PatelAnaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, UK; Royal Brompton and Harefield Clinical Group, Guy's andSt Thomas' NHS Foundation Trust, London, UK.
Karen Piper-HanleyFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Krisnah PoinasamyAsthma + Lung UK, London, UK.
Betty RamanRadcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Matthew RichardsonThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Pilar Rivera-OrtegaManchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
Sarah L Rowland-JonesInfection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Alex V RowlandsDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Ruth M SaundersThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Janet T ScottMRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
Marco SerenoThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Ajay M ShahFaculty of Life Sciences & Medicine, King's College Hospital NHS Foundation Trust, London, UK; Kings College London, London, UK.
Aarti ShikotraNIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Amisha SingapuriThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Stefan C StanelFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
Mathew ThorpeCentre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
Daniel G WoottonInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Thomas YatesDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK.
R Gisli JenkinsNational Heart & Lung Institute, Imperial College London, London, UK.
Sally J SinghThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
William D-C ManNational Heart & Lung Institute, Imperial College London, London, UK; Kings College London, London, UK; Royal Brompton and Harefield Clinical Group, Guy's andSt Thomas' NHS Foundation Trust, London, UK.
Christopher E BrightlingThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Louise V WainThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Department of Population Health Sciences, University of Leicester, Leicester, UK.
Joanna C PorterUCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK; ILD Service, University College London Hospital, London, UK.
A A Roger ThompsonInfection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Alex HorsleyFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
Philip L MolyneauxNational Heart & Lung Institute, Imperial College London, London, UK.
Rachael A EvansThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; University Hospitals of Leicester NHS Trust, Leicester, UK.
Samuel E JonesInstitute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
Martin K RutterFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK.
John F BlaikleyFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK. Electronic address: john.blaikley@manchester.ac.uk.
PHOSP-COVID Study Collaborative Group
Manchester Academic Health Science Centre · GBUniversity of Leicester · GBNIHR Southampton Biomedical Research Centre · GBUniversity of Helsinki · FIUniversity of Manchester · GBImperial College London · GBKing's College London · GBNHS Lothian · GBSwansea University · GBSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity of Edinburgh · GBUniversity College Hospital · GBUniversity of Liverpool · GBImperial College Healthcare NHS Trust · GBNottingham University Hospitals NHS Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBLeicester General Hospital · GBMRC University of Glasgow Centre for Virus Research · GBUniversity of Dundee · GBUniversity of Oxford · GB

Funding

British Heart Foundation CH/16/1/32013British Heart Foundation FS/18/13/33281British Heart Foundation RE/18/3/34214British Heart Foundation SP/17/16/33519Department of Health COV0319Department of Health NIHR203308Department of Health NIHR300669Department of Health RP-2017-08-ST2-014Medical Research Council MC_PC_19026Medical Research Council MC_PC_20031Medical Research Council MC_PC_20060Medical Research Council MC_UU_00034/6Medical Research Council MR/M008894/1Medical Research Council MR/S004041/1Medical Research Council MR/T032529/1Medical Research Council MR/V027859/1Medical Research Council MR/V040162/1Medical Research Council MR/W006111/1Wellcome Trust 206330/Z/17/ZWellcome Trust 209553/Z/17/ZWellcome Trust 216606/Z/19/Z
6 · The paper itself

Abstract

backgroundSleep disturbance is common following hospital admission both for COVID-19 and other causes. The clinical associations of this for recovery after hospital admission are poorly understood despite sleep disturbance contributing to morbidity in other scenarios. We aimed to investigate the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and to assess whether this was associated with dyspnoea.

methodsCircCOVID was a prospective multicentre cohort substudy designed to investigate the effects of circadian disruption and sleep disturbance on recovery after COVID-19 in a cohort of participants aged 18 years or older, admitted to hospital for COVID-19 in the UK, and discharged between March, 2020, and October, 2021. Participants were recruited from the Post-hospitalisation COVID-19 study (PHOSP-COVID). Follow-up data were collected at two timepoints: an early time point 2-7 months after hospital discharge and a later time point 10-14 months after hospital discharge. Sleep quality was assessed subjectively using the Pittsburgh Sleep Quality Index questionnaire and a numerical rating scale. Sleep quality was also assessed with an accelerometer worn on the wrist (actigraphy) for 14 days. Participants were also clinically phenotyped, including assessment of symptoms (ie, anxiety [Generalised Anxiety Disorder 7-item scale questionnaire], muscle function [SARC-F questionnaire], dyspnoea [Dyspnoea-12 questionnaire] and measurement of lung function), at the early timepoint after discharge. Actigraphy results were also compared to a matched UK Biobank cohort (non-hospitalised individuals and recently hospitalised individuals). Multivariable linear regression was used to define associations of sleep disturbance with the primary outcome of breathlessness and the other clinical symptoms. PHOSP-COVID is registered on the ISRCTN Registry (ISRCTN10980107).

findings2320 of 2468 participants in the PHOSP-COVID study attended an early timepoint research visit a median of 5 months (IQR 4-6) following discharge from 83 hospitals in the UK. Data for sleep quality were assessed by subjective measures (the Pittsburgh Sleep Quality Index questionnaire and the numerical rating scale) for 638 participants at the early time point. Sleep quality was also assessed using device-based measures (actigraphy) a median of 7 months (IQR 5-8 months) after discharge from hospital for 729 participants. After discharge from hospital, the majority (396 [62%] of 638) of participants who had been admitted to hospital for COVID-19 reported poor sleep quality in response to the Pittsburgh Sleep Quality Index questionnaire. A comparable proportion (338 [53%] of 638) of participants felt their sleep quality had deteriorated following discharge after COVID-19 admission, as assessed by the numerical rating scale. Device-based measurements were compared to an age-matched, sex-matched, BMI-matched, and time from discharge-matched UK Biobank cohort who had recently been admitted to hospital. Compared to the recently hospitalised matched UK Biobank cohort, participants in our study slept on average 65 min (95% CI 59 to 71) longer, had a lower sleep regularity index (-19%; 95% CI -20 to -16), and a lower sleep efficiency (3·83 percentage points; 95% CI 3·40 to 4·26). Similar results were obtained when comparisons were made with the non-hospitalised UK Biobank cohort. Overall sleep quality (unadjusted effect estimate 3·94; 95% CI 2·78 to 5·10), deterioration in sleep quality following hospital admission (3·00; 1·82 to 4·28), and sleep regularity (4·38; 2·10 to 6·65) were associated with higher dyspnoea scores. Poor sleep quality, deterioration in sleep quality, and sleep regularity were also associated with impaired lung function, as assessed by forced vital capacity. Depending on the sleep metric, anxiety mediated 18-39% of the effect of sleep disturbance on dyspnoea, while muscle weakness mediated 27-41% of this effect.

interpretationSleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.

fundingUK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council.

Indexed as

COVID-19Sleep Wake DisordersHospitalizationHospitalsHumansLungProspective StudiesSleepUnited Kingdom

Identifiers

PMID37072018
PMCPMC10156429
OpenAlexW4365814786

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.